Treatment of locally advanced esophageal cancer with surgery and chemoradiation.
OBJECTIVE
This article reviews developments in the treatment of locally advanced esophageal cancer with surgery and chemoradiation published in 2007.


RESULTS
Overall long-term survival is the same for patients after transhiatal or transthoracic esophagectomy. The pathology report of the resected specimen should contain information on lymph node status, such as size, location and lymph node ratio. If surgery is performed in patients with advanced esophageal cancer, there is small survival advantage if combined with neoadjuvant therapy, that is chemoradiation. Prognostic factors are a good performance status, a major response to chemoradiation and an early metabolic response with fluorine-18 fluorodeoxyglucose PET. Definitive chemoradiation may have similar results as combination treatment including surgery in selected patients with esophageal squamous cell cancer. Salvage surgery should be considered if definitive chemoradiation fails, provided that an R0 resection can be performed. Nutritional status is a prognostic factor in patients undergoing treatment of esophageal cancer.


CONCLUSIONS
In 2007, refinements of the nodal status in the tumor, node, metastasis system were proposed. Chemoradiation followed by surgery is increasingly being used in patients with advanced esophageal cancer. Evidence suggests that definitive chemoradiation could be a reliable treatment option in selected patients with esophageal squamous cell cancer.
Siersema
Peter D
PD
Department of Gastroenterology & Hepatology and Surgery, University Medical Center Utrecht, The Netherlands. p.d.siersema@umcutrecht.nl
van Hillegersberg
Richard
R
D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D016629:Esophagectomy; D006801:Humans; D008197:Lymph Node Excision; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant